DAB2IP and neoplasm: Our prior pilot study analyzed 46 men's diagnostic prostate biopsies with high‐risk disease for DAB2IP expression and showed a strong correlation between pretreatment tumor DAB2IP reduction and worse clinical outcome with only 2.7 years of median follow up.